ATE538109T1 - Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine - Google Patents

Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine

Info

Publication number
ATE538109T1
ATE538109T1 AT07822643T AT07822643T ATE538109T1 AT E538109 T1 ATE538109 T1 AT E538109T1 AT 07822643 T AT07822643 T AT 07822643T AT 07822643 T AT07822643 T AT 07822643T AT E538109 T1 ATE538109 T1 AT E538109T1
Authority
AT
Austria
Prior art keywords
obesity
diabetes
treatment
benzothiadiazine
hydroxyphenyl
Prior art date
Application number
AT07822643T
Other languages
English (en)
Inventor
Preben Houlberg Olesen
Anders Klarskov Petersen
Flemming Elmelund Nielsen
Lise Brown Christiansen
Holger Claus Hansen
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE538109T1 publication Critical patent/ATE538109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07822643T 2006-11-15 2007-11-15 Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine ATE538109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601488 2006-11-15
PCT/EP2007/062408 WO2008059025A1 (en) 2006-11-15 2007-11-15 Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes

Publications (1)

Publication Number Publication Date
ATE538109T1 true ATE538109T1 (de) 2012-01-15

Family

ID=39016016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07822643T ATE538109T1 (de) 2006-11-15 2007-11-15 Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine

Country Status (6)

Country Link
US (1) US8022066B2 (de)
EP (1) EP2086951B1 (de)
AT (1) ATE538109T1 (de)
CA (1) CA2669874A1 (de)
ES (1) ES2377322T3 (de)
WO (1) WO2008059025A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3269955A (en) 1963-05-10 1966-08-30 American Cyanamid Co Method for emitting fluorescent light using fluorescent quinazolones
US3526627A (en) 1969-06-05 1970-09-01 American Cyanamid Co Method for preparation of quinazolones
JPS6025984A (ja) 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
US5240962A (en) 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU4345297A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
EP0981526B1 (de) 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1998045292A1 (en) 1997-12-02 1998-10-15 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
EP1123297A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Verbindungen, ihre herstellung und verwendung
AU6190199A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
KR20010086126A (ko) 1998-12-18 2001-09-07 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체 및 그의 제법 및 용도
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
IL145958A0 (en) 1999-04-16 2002-07-25 Reddy Research Foundation Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
EP1171431A1 (de) 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre anwendung und ihre verwendung
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542246A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
HUP0200807A3 (en) 1999-04-20 2003-03-28 Novo Nordisk As Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AU2001259354A1 (en) 2000-05-02 2001-11-12 Smith Kline Beecham Corporation Phosphate transport inhibitors
US6790569B2 (en) 2000-06-13 2004-09-14 Eastman Kodak Company Color photothermographic elements comprising phenolic thermal solvents
CA2416229C (en) 2000-07-20 2007-09-18 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
EP1575575B1 (de) 2002-11-08 2010-05-19 High Point Pharmaceuticals, LLC Sichere chemische entkuppler zur behandlung von fettsucht
WO2004065370A1 (en) 2003-01-23 2004-08-05 Crystalgenomics, Inc. Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
AU2004292536A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. Methods for producing olfactory GPCRS
EP1689700A1 (de) * 2003-11-25 2006-08-16 Novo Nordisk A/S Neue salicylsäure anilide
EP1758856A2 (de) 2004-05-04 2007-03-07 Novo Nordisk A/S Indolderivate zur behandlung von obesitas
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US7705157B2 (en) 2004-12-16 2010-04-27 Symyx Solutions, Inc. Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US20100249161A1 (en) 2006-11-15 2010-09-30 Anders Klarskov Petersen 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes

Also Published As

Publication number Publication date
EP2086951B1 (de) 2011-12-21
US20090325941A1 (en) 2009-12-31
EP2086951A1 (de) 2009-08-12
WO2008059025A1 (en) 2008-05-22
CA2669874A1 (en) 2008-05-22
US8022066B2 (en) 2011-09-20
ES2377322T3 (es) 2012-03-26

Similar Documents

Publication Publication Date Title
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
EA201000714A1 (ru) Соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продуцирования бета амилоидного пептида
FR2983199B1 (fr) Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE367161T1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EP1805156A4 (de) Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE448230T1 (de) Für die behandlung von obesitas geeignete tricyclische amidderivate
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201070423A1 (ru) Диарильные соединения оксадиазолов
WO2008063781A3 (en) Chemical compounds as cannabinoid receptor ligands
NO20081562L (no) Syntetiske metoder og mellomprodukt for stereoisomeriske forbindelser som er nyttige for behandlingen av gastrointestinale og sentralnervesystemersykdommer
DE602007009865D1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
EA200700717A1 (ru) Сульфонамиды
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
CU23820A3 (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención
NO20055741L (no) Nye kjemiske forbindelser
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
ATE526953T1 (de) Verwendung von 5-ht7-rezeptor-agonisten zur behandlung von schmerzen
EP2214776C0 (de) Gerät zur behandlung von impotenz
EA200900261A1 (ru) Применение эсцина